Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
Patrick Mercer, President and CEO of IRIDEX CORP (IRIX), reported a sale of 23,850 shares on 10/01/2025 at a reported price of $1.13 per share. After the transaction Mercer beneficially owns 392,007 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 09/12/2025. The Form 4 shows two non-derivative acquisitions: 250 shares at $1.37 and 1,200 shares at $1.36, for a total of 1,450 shares acquired. Following the transactions, the filing reports 61,950 shares beneficially owned. The form is signed by an attorney-in-fact on 09/15/2025.
Romeo R. Dizon, the Chief Financial Officer and a director of Iridex Corp (IRIX), reported insider purchases on 09/10/2025. He acquired 1,000 shares at $1.33 and 500 shares at $1.36, bringing his total reported beneficial ownership to 59,250 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025.
Iridex Corp (IRIX) insider purchase: Chief Financial Officer Romeo R. Dizon purchased 1,500 shares of Iridex common stock on 09/09/2025 at a price of $1.37 per share. Following the transaction, the reporting person beneficially owns 57,750 shares. The Form 4 was filed indicating the transaction code "P" and was signed by an attorney-in-fact on 09/10/2025.
IRIDEX Corporation reports that it has regained compliance with Nasdaq’s continued listing standards. Based on its Form 10-Q for the quarter ended June 28, 2025, the company now meets the Nasdaq Listing Rule 5550(b)(1) minimum stockholders’ equity requirement of $2,500,000 for the Nasdaq Capital Market.
Nasdaq has informed IRIDEX that the prior non-compliance matter is closed, removing the earlier listing deficiency. The company also issued a press release on September 9, 2025 to highlight its renewed compliance with the stockholders’ equity requirement.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported an insider purchase of common stock. On 09/08/2025 he acquired 500 shares at $1.40 per share, increasing his reported beneficial ownership to 56,250 shares. The Form 4 was signed on 09/09/2025 by an attorney-in-fact.
Iridex Corp (IRIX) insider purchase reported: Chief Financial Officer Romeo R. Dizon acquired 1,000 shares of Iridex common stock on 09/05/2025 at $1.35 per share, increasing his beneficial ownership to 55,750 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025. No derivative transactions or additional details were reported.
Iridex Corp (IRIX) Form 4: Romeo R. Dizon, identified as the Chief Financial Officer, reported three transactions on 09/04/2025. The filing shows acquisitions of 404, 96, and 625 common shares at prices of $1.32, $1.345, and $1.39 respectively. After those transactions the filing lists beneficial ownership totals of 54,029, 54,125, and 54,750 shares. The form was signed by an attorney-in-fact on 09/05/2025.
Iridex Corp (IRIX) insider filing shows Chief Financial Officer Romeo R. Dizon, via attorney-in-fact, purchased 625 shares of common stock on 09/03/2025 at $1.36 per share, bringing his beneficial ownership to 53,625 shares.
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported a purchase of 625 shares of the company's common stock on 09/02/2025 at a price of $1.34 per share, increasing his beneficial ownership to 53,000 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025. The filing documents a routine insider purchase by a named officer and identifies no derivative transactions or additional disclosures.